Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 326

Sort by

Sort Order Select

Journal Articles

Evaluating Minimal Residual Disease Negativity As a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials

Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Anastasios Ntanasis-Stathopoulos, Panagiotis Malandrakis, Efstathios Kastritis, Meletios A. Dimopoulos, Evangelos Terpos, Maria Gavriatopoulou

Blood (2024) 144 (Supplement 1): 4696.

https://doi.org/10.1182/blood-2024-194398

Published: 2024

Journal Articles

Ultra Long-Term Myeloma Survivors (>15 years): Characteristics of a Unique Group of Myeloma Patients

Meletios-Athanasios Dimopoulos, Despina Fotiou, Foteini Theodorakakou, Irene Solia, Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Erasmia Psimenou, Nikolaos Kanellias, Maria Roussou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 1948.

https://doi.org/10.1182/blood-2024-203910

Published: 2024

Journal Articles

Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium

Murali Janakiram, Carlyn Rose Tan, Rakesh Popat, Joaquín Martínez Lopez, Efstathios Kastritis, Chris Lau, Wee-Joo Chng, Prashant Kapoor, Hira Mian, Susan Bal, Ajay K. Nooka, Andre De Menezes Silva Corraes, Magdalena Corona, Arnab Chowdhury, Yi Lin, Thomas G Martin, Amrita Y Krishnan

Blood (2024) 144 (Supplement 1): 3368.

https://doi.org/10.1182/blood-2024-211167

Published: 2024

Journal Articles

An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response

Blood (2024) 144 (Supplement 1): 3328.

https://doi.org/10.1182/blood-2024-200038

Published: 2024

Journal Articles

Clinical Outcomes in Consecutive Newly Diagnosed Patients with Waldenstrom's Macroglobulinemia Treated with Different Regimens in the Real-World Setting

Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Vasiliki Spiliopoulou, Charalampos Filippatos, Magdalini Migkou, Panagiotis Malandrakis, Foteini Theodorakakou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 4397.

https://doi.org/10.1182/blood-2024-202610

Published: 2024

Journal Articles

Detection of B Cell Lymphomas By a Simple Epigenetic Blood Test

Blood (2024) 144 (Supplement 1): 1582.

https://doi.org/10.1182/blood-2024-207707

Published: 2024

Journal Articles

The Combined Treatment of Btkis with Venetoclax Exhibits an Enhanced Therapeutic Effect on Waldenström Macroglobulinemia Cells Bearing CXCR4 Mutations

Eleni Kalafati, Kostantina Taouxi, Ourania Theologi, Nefeli Mavrianou Koutsoukou, Ioannis Kollias, Christine-Ivy Liacos, Alexandra Papadimou, Katerina Chrisostomidou, Maria Gavriatopoulou, Meletios Dimopoulos, Evangelos Terpos, Nicholas P. Anagnou, Efstathios Kastritis, Tina Bagratuni

Blood (2024) 144 (Supplement 1): 1603.

https://doi.org/10.1182/blood-2024-205460

Published: 2024

Journal Articles

Genomic Characterization of Ibrutinib-Resistant Waldenström's Macroglobulinemia

Tina Bagratuni, Christos Vlachos, Maria Sakkou, Ioannis Kollias, Ourania Theologi, Nefeli Mavrianou Koutsoukou, Christine-Ivy Liacos, Kostantina Taouxi, Alexandra Papadimou, Katerina Chrisostomidou, Despina Fotiou, Maria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis, Meletios-Athanasios Dimopoulos

Blood (2024) 144 (Supplement 1): 1600.

https://doi.org/10.1182/blood-2024-200652

Published: 2024

Journal Articles

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Monique C Minnema, Meletios-Athanasios Dimopoulos, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Antoine Huart, Karim Belhadj Merzoug, Stavros Golfinopoulos, Nasia Antoniou, Giorgos Psarros, Pieter Sonneveld, Giovanni O. Palladini

Blood (2024) 144 (Supplement 1): 1979.

https://doi.org/10.1182/blood-2024-202932

Published: 2024

Journal Articles

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Panagiotis Malandrakis, Ioannis V Kostopoulos, Ioannis Ntanasis-Stathopoulos, Irene Solia, Foteini Theodorakakou, Vasiliki Spiliopoulou, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Kostantina Taouxi, Alexandra Papadimou, Christine-Ivy Liacos, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Ourania Tsitsilonis, Evangelos Terpos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 1020.

https://doi.org/10.1182/blood-2024-203751

Published: 2024

Journal Articles

Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants

Blood (2024) 144 (Supplement 1): 1017.

https://doi.org/10.1182/blood-2024-205705

Published: 2024

Journal Articles

Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group

Blood (2024) 144 (Supplement 1): 1991.

https://doi.org/10.1182/blood-2024-203519

Published: 2024

Journal Articles

A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma

Ioannis Ntanasis-Stathopoulos, Ioannis V Kostopoulos, Panagiotis Malandrakis, Pantelis Rousakis, Chrysanthi Panteli, Evangelos Eleutherakis-Papaiakovou, Vasiliki Spiliopoulou, Georgia Dimitrakopoulou, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Nikolaos Kanellias, Maria Gavriatopoulou, Efstathios Kastritis, Meletios A. Dimopoulos, Ourania Tsitsilonis, Evangelos Terpos

Blood (2024) 144 (Supplement 1): 490.

https://doi.org/10.1182/blood-2024-194090

Published: 2024

Journal Articles

Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial ( ECWM-2 ) of the European Consortium for Waldenström's Macroglobulinemia

Blood (2024) 144 (Supplement 1): 859.

https://doi.org/10.1182/blood-2024-200604

Published: 2024

Journal Articles

Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Blood (2024) 144 (Supplement 1): 5166.

https://doi.org/10.1182/blood-2024-210518

Published: 2024

Journal Articles

Determining the Mutational Landscape of Waldenström's Macroglobulinemia By Liquid Biopsy: Results of the Prospective Ecwm-2 Trial of the European Consortium for Waldenström's Macroglobulinemia

Philipp Nakov, Daniela Drandi, Lisa Marie Kaiser, Dajana Kaszynski, Alexander Grunenberg, Jasmin Mark, Elke Runge, Meletios Dimopoulos, Efstathios Kastritis, Tina Bagratuni, Christian Buske, Christiane Pott, Simone Ferrero, Mouhamad Khouja

Blood (2024) 144 (Supplement 1): 4352.

https://doi.org/10.1182/blood-2024-204645

Published: 2024

Journal Articles

Measurable Residual Disease and Peripheral Residual Disease to Assess Treatment Response in Real-World Patients with Newly Diagnosed Multiple Myeloma

Noemi Puig, Panagiotis Malandrakis, Cristina Agullo, Sergio Castro, Teresa Contreras, Veronica Gonzalez-Calle, Beatriz Rey-Búa, Borja Puertas Martínez, Evangelos Terpos, Meletios A. Dimopoulos, Maria- Victoria Mateos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 4694.

https://doi.org/10.1182/blood-2024-209661

Published: 2024

Journal Articles

Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group

Evangelos Terpos, Efstathios Kastritis, Sosana Delimpasi, Maria Kotsopoulou, Konstantina Papathanasiou, Vasiliki Labropoulou, Eirini Katodrytou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Giorgos Psarros, Maria Gavriatopoulou, Meletios Dimopoulos

Blood (2024) 144 (Supplement 1): 3361.

https://doi.org/10.1182/blood-2024-204707

Published: 2024

Journal Articles

Less Is More: Deciphering the Association between Ocular Adverse Events and Clinical Activity of Belantamab Mafodotin in Multiple Myeloma

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Giorgos Psarros, Efstathios Kastritis, Meletios Dimopoulos

Blood (2024) 144 (Supplement 1): 3380.

https://doi.org/10.1182/blood-2024-209915

Published: 2024

Journal Articles

Circular RNA Profiling Using High-Accuracy Long-Read Nanopore Sequencing of Multiple Myeloma Cell Lines Reveals the Wide Diversity of the Circular Transcriptome

Maria Papatsirou, Christos Kontos, Ioannis Ntanasis-Stathopoulos, Christina Sotiropoulou, Christine-Ivy Liacos, Maria Gavriatopoulou, Margaritis Avgeris, Efstathios Kastritis, Meletios Dimopoulos, Jerome Moreaux, Andreas Scorilas, Evangelos Terpos

Blood (2024) 144 (Supplement 1): 3285.

https://doi.org/10.1182/blood-2024-206812

Published: 2024

NARROW

Evaluating Minimal Residual Disease Negativity As a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials

Ultra Long-Term Myeloma Survivors (>15 years): Characteristics of a Unique Group of Myeloma Patients

Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium

An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response

Clinical Outcomes in Consecutive Newly Diagnosed Patients with Waldenstrom's Macroglobulinemia Treated with Different Regimens in the Real-World Setting

Detection of B Cell Lymphomas By a Simple Epigenetic Blood Test

The Combined Treatment of Btkis with Venetoclax Exhibits an Enhanced Therapeutic Effect on Waldenström Macroglobulinemia Cells Bearing CXCR4 Mutations

Genomic Characterization of Ibrutinib-Resistant Waldenström's Macroglobulinemia

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants

Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group

A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma

Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial ( ECWM-2 ) of the European Consortium for Waldenström's Macroglobulinemia

Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Determining the Mutational Landscape of Waldenström's Macroglobulinemia By Liquid Biopsy: Results of the Prospective Ecwm-2 Trial of the European Consortium for Waldenström's Macroglobulinemia

Measurable Residual Disease and Peripheral Residual Disease to Assess Treatment Response in Real-World Patients with Newly Diagnosed Multiple Myeloma

Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group

Less Is More: Deciphering the Association between Ocular Adverse Events and Clinical Activity of Belantamab Mafodotin in Multiple Myeloma

Circular RNA Profiling Using High-Accuracy Long-Read Nanopore Sequencing of Multiple Myeloma Cell Lines Reveals the Wide Diversity of the Circular Transcriptome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only